SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 227 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,731,892 | -8.3% | 62,818 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $1,888,309 | -17.0% | 62,818 | -0.0% | 0.00% | 0.0% |
| Q1 2023 | $2,276,186 | -9.9% | 62,826 | -11.3% | 0.00% | 0.0% |
| Q4 2022 | $2,525,293 | +1.8% | 70,796 | -3.4% | 0.00% | 0.0% |
| Q3 2022 | $2,480,000 | +24.1% | 73,266 | +6.0% | 0.00% | 0.0% |
| Q2 2022 | $1,999,000 | -15.2% | 69,105 | -5.2% | 0.00% | 0.0% |
| Q1 2022 | $2,356,000 | +11.1% | 72,899 | +0.2% | 0.00% | 0.0% |
| Q4 2021 | $2,121,000 | +9.5% | 72,723 | +0.1% | 0.00% | 0.0% |
| Q3 2021 | $1,937,000 | -20.8% | 72,630 | -8.6% | 0.00% | 0.0% |
| Q2 2021 | $2,447,000 | +26.2% | 79,480 | +7.3% | 0.00% | 0.0% |
| Q1 2021 | $1,939,000 | -21.3% | 74,056 | -24.4% | 0.00% | 0.0% |
| Q4 2020 | $2,464,000 | +62.1% | 97,936 | +34.3% | 0.00% | 0.0% |
| Q3 2020 | $1,520,000 | -13.9% | 72,940 | -1.9% | 0.00% | 0.0% |
| Q2 2020 | $1,766,000 | +36.0% | 74,350 | +3.0% | 0.00% | 0.0% |
| Q1 2020 | $1,299,000 | -24.0% | 72,190 | +0.1% | 0.00% | 0.0% |
| Q4 2019 | $1,710,000 | -54.6% | 72,090 | -47.4% | 0.00% | -50.0% |
| Q3 2019 | $3,764,000 | -23.6% | 136,960 | -8.0% | 0.00% | -33.3% |
| Q2 2019 | $4,926,000 | +10.2% | 148,860 | +16.7% | 0.00% | 0.0% |
| Q1 2019 | $4,470,000 | +5.5% | 127,560 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $4,238,000 | -34.2% | 127,560 | -0.3% | 0.00% | -25.0% |
| Q3 2018 | $6,443,000 | -15.9% | 127,960 | 0.0% | 0.00% | -20.0% |
| Q2 2018 | $7,658,000 | +55.6% | 127,960 | +19.1% | 0.01% | +25.0% |
| Q1 2018 | $4,921,000 | +9.1% | 107,440 | -5.1% | 0.00% | +33.3% |
| Q4 2017 | $4,511,000 | -0.4% | 113,210 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $4,528,000 | -20.9% | 113,210 | -14.7% | 0.00% | -25.0% |
| Q2 2017 | $5,721,000 | +21.4% | 132,740 | -11.9% | 0.00% | 0.0% |
| Q1 2017 | $4,714,000 | -21.6% | 150,610 | -36.8% | 0.00% | -20.0% |
| Q4 2016 | $6,015,000 | +10.3% | 238,210 | +8.1% | 0.01% | 0.0% |
| Q3 2016 | $5,451,000 | +107.3% | 220,430 | +70.8% | 0.01% | +150.0% |
| Q2 2016 | $2,629,000 | +139.9% | 129,070 | +79.6% | 0.00% | +100.0% |
| Q1 2016 | $1,096,000 | +45.2% | 71,870 | +28.0% | 0.00% | 0.0% |
| Q4 2015 | $755,000 | -13.5% | 56,140 | -9.8% | 0.00% | 0.0% |
| Q3 2015 | $873,000 | -15.3% | 62,240 | +2.5% | 0.00% | 0.0% |
| Q2 2015 | $1,031,000 | -36.0% | 60,700 | -54.5% | 0.00% | 0.0% |
| Q1 2015 | $1,611,000 | +4502.9% | 133,270 | +3073.1% | 0.00% | – |
| Q4 2014 | $35,000 | -52.1% | 4,200 | -50.0% | 0.00% | – |
| Q3 2014 | $73,000 | -20.7% | 8,400 | 0.0% | 0.00% | – |
| Q2 2014 | $92,000 | +1433.3% | 8,400 | +1086.4% | 0.00% | – |
| Q1 2014 | $6,000 | -85.0% | 708 | -86.7% | 0.00% | – |
| Q4 2013 | $40,000 | -55.1% | 5,308 | -56.2% | 0.00% | – |
| Q3 2013 | $89,000 | -11.0% | 12,108 | -22.0% | 0.00% | – |
| Q2 2013 | $100,000 | – | 15,526 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |